



BRITISH GENERIC MANUFACTURERS ASSOCIATION

January 16th, 2015

BGMA and MHRA Come Together for Quality Forum

The British Generic Manufacturers Association (BGMA) will stage the next meeting of its Quality Forum – in conjunction with the MHRA - on Tuesday, February 24th.

The Quality Forum was launched last year with the MHRA to focus on ensuring the manufacturing quality of generic medicines in the UK.

The group meets three times a year to share and discuss the latest issues and provide an open channel between industry and the regulator.

The forum brings together generic medicines companies, those who provide manufacturing and quality control services, as well as the MHRA. Topics covered have included data integrity, current approaches to inspection, trends and the auditing that companies perform themselves.

The specific topics for the next meeting will include investigating anomalies, avoiding cross contamination and protecting continuity of supply.

Paul Fleming, the BGMA's Technical Director, said: "Since we launched the Quality Forum we have been very pleased with the interest and engagement we have received. Issues of quality are critical to ensuring the right patient, gets the right medicine at the right time."

The forum is open to members and associate members of the BGMA and for further information please contact email jeremy.durrant@britishgenerics.co.uk. Full information is available on the website www.britishgenerics.co.uk.

ENDS

For further information contact:

Jeremy Durrant, 020 7866 7883 / 07792 918648

jeremy.durrant@britishgenerics.co.uk

Notes for Editors:

The British Generic Manufacturers Association represents the interests of UK-based manufacturers and suppliers of generic medicines and promotes the development and understanding of the generic medicines industry in the United Kingdom.

Press Release

Generic medicines contain the same active ingredient and are as effective as the equivalent brand and cost much less, making the NHS drugs bill affordable. More than two thirds of all medicines dispensed by the NHS are generics yet they cost only around 29% of the NHS drugs bill, a saving of more than £12.5billion in England & Wales alone. Without generics, the NHS drugs bill would be approximately twice its current level.

We represent the views and interests of our members and industry to the UK government, the devolved administrations, regulators, other relevant third parties, including where appropriate the Institutions of the European Union.